TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Stock data | 2024 | Change |
---|---|---|
Price | $0.66000003 | N/A |
Market Cap | $446.49K | N/A |
Shares Outstanding | 676.50K | N/A |
Employees | 60.00 | N/A |